Fosun International (0656) AI Stock Analysis

• Market Cap: HK$33.89B
• Dividend Yield: 0.44%
• Average Volume (3M): 7.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.09
• Revenue Growth: -8.93%
• EPS Growth: -698.78%
• Country: HK
• Employees: 104,000
• Sector: Industrials
• Sector Strength: 72
• Industry: Conglomerates
• EPS (TTM): 0.09
• Shares Outstanding: 8,166,663,000
• 10 Day Avg. Volume: 5,394,621
• 30 Day Avg. Volume: 7,085,908
• PEG Ratio: 0.02
• Price to Book (P/B): 0.29
• Price to Sales (P/S): 0.18
• P/FCF Ratio: 2.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: HK$4.00 ▼(-7.62% Downside)

The overall stock score is primarily influenced by significant financial challenges, including a highly leveraged balance sheet and weak cash flow. Technical indicators further suggest bearish momentum, while valuation metrics indicate potential overvaluation. These factors collectively contribute to a low overall score.

Positive Factors

Diversified business model

A multi-segment model across health, consumer lifestyle, insurance/asset management and manufacturing spreads revenue risk and creates multiple, complementary cash-generation channels. This structural diversification supports resilience across economic cycles and enables cross-selling and capital allocation flexibility.

Scale and operating footprint

A large operational footprint and employee base signal meaningful scale advantages in distribution, operations, and talent. Scale supports bargaining power with suppliers, the ability to invest in systems and R&D, and the capacity to integrate and grow portfolio companies over the medium term.

Improving operating margins

Stable gross margins and improving EBIT/EBITDA versus two years ago indicate operational improvements and cost discipline across businesses. Sustained margin recovery would enhance cash generation and ability to fund strategic initiatives even if top-line growth remains uneven.

Negative Factors

High financial leverage

Substantial leverage reduces financial flexibility and raises refinancing and interest-rate risks. High debt levels constrain capital allocation, increase vulnerability to market volatility, and can force asset sales or dilute shareholders if sustained, weakening long-term strategic optionality.

Weak cash generation

Absent free cash flow and volatile operating cash flows undermine the group's ability to service debt, invest in growth, or support portfolio companies organically. Persistent weak cash generation may necessitate asset disposals or external financing, increasing execution risk over months.

Declining revenue and recent losses

Ongoing revenue decline together with a negative net margin points to structural demand or profitability challenges in core operations. Without sustainable top-line recovery or margin fixes, losses can erode equity, limit reinvestment, and worsen leverage dynamics over the medium term.

Fosun International Business Overview & Revenue Model

Company Description

Fosun International Limited operates in health, happiness, wealth, and intelligent manufacturing sectors in Mainland China, Portugal, and internationally. It operates in five segments: Health, Happiness, Insurance, Asset Management, and Intelligent Manufacturing. The Health segment engages in the research, development, manufacture, sale, and trading of pharmaceutical, biopharmaceutical, and health products; and provision of medical and health management services. The Happiness segment operates and invests in tourism and leisure, fashion consumer, and lifestyle industries. The Insurance segment operates and invests in the insurance markets. The Asset Management segment engages in the asset management and market investments activities. The Intelligent Manufacturing segment operates and invests in the intelligent manufacturing business; and produces iron and steel ore. It is also involved in the capital investment and management, property development, retail, and reinsurance business; manufacture and sale of iron and steel products; provision of banking and financial, and medical consultation services, as well as digital solutions. The company was founded in 1992 and is based in Shanghai, China. Fosun International Limited is a subsidiary of Fosun Holdings Limited.

How the Company Makes Money

Fosun International generates revenue through various key streams. Primarily, it earns income from its healthcare segment, which includes pharmaceutical manufacturing, health management services, and medical devices. The insurance sector contributes another significant revenue source, with premiums collected from its insurance operations. Additionally, Fosun has substantial investments in real estate and tourism, which provide rental income and profits from property development. The company also benefits from its asset management services, earning fees from managing investments for clients. Strategic partnerships with other firms and acquisitions further enhance its revenue potential, allowing Fosun to tap into new markets and expand its product offerings.

Fosun International Financial Statement Overview

Summary

Fosun International faces significant financial challenges with mixed income performance, a highly leveraged balance sheet, and weak cash flow. The company needs to address its profitability issues and manage its debt levels to improve financial health.

Income Statement

The income statement reveals a mixed performance. Gross profit margin is stable; however, there is a negative net profit margin indicating losses in the most recent period. Revenue has decreased slightly compared to the previous year, reflecting a challenging environment. EBIT and EBITDA margins have improved compared to two years ago, but recent losses are concerning.

Balance Sheet

The balance sheet shows a moderate position with a high debt-to-equity ratio, indicating substantial leverage. Stockholders' equity has decreased, but the equity ratio is reasonable, suggesting some balance in financial structure. However, the declining equity and increasing debt are potential risks.

Cash Flow

The cash flow statement is weak with no available free cash flow and operating cash flow figures for the latest period. Previous periods show negative free cash flow growth and volatility in cash flow ratios, highlighting operational and investment challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	181.59B	192.14B	198.20B	182.43B	161.29B	136.74B
Gross Profit	49.65B	51.60B	50.80B	47.31B	55.65B	50.59B
EBITDA	429.15M	329.02M	30.50B	1.02B	4.05B	5.02B
Net Income	-4.41B	-4.35B	1.38B	-831.80M	10.08B	8.00B
Balance Sheet
Total Assets	735.69B	796.53B	808.39B	806.38B	806.28B	767.72B
Cash, Cash Equivalents and Short-Term Investments	111.54B	133.09B	133.27B	150.38B	166.93B	166.95B
Total Debt	222.11B	241.86B	233.57B	245.92B	257.87B	250.87B
Total Liabilities	538.35B	598.99B	599.81B	607.30B	603.16B	574.64B
Stockholders Equity	118.14B	118.10B	124.94B	120.73B	131.00B	127.81B
Cash Flow
Free Cash Flow	13.20B	15.61B	-3.35B	-5.45B	-9.64B	2.73B
Operating Cash Flow	16.24B	26.88B	9.82B	1.76B	-3.32B	8.89B
Investing Cash Flow	-2.72B	-126.97M	17.59B	35.58B	-536.96M	612.52M
Financing Cash Flow	-18.06B	-14.27B	-39.67B	-38.12B	-3.66B	2.29B

Fosun International Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0656, the sentiment is Negative. The current price of 4.33 is above the 20-day moving average (MA) of 4.28, below the 50-day MA of 4.56, and below the 200-day MA of 4.83, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 38.05 is Neutral, neither overbought nor oversold. The STOCH value of 63.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0656.

Fosun International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0053	80 Outperform	HK$23.20B	5.91	6.18%	5.00%	7.45%	11.56%
0267	72 Outperform	HK$363.92B	6.08	7.65%	5.15%	2.45%	-0.36%
0392	66 Neutral	HK$44.53B	7.72	6.26%	4.94%	―	―
0001	64 Neutral	HK$242.25B	32.83	1.42%	4.02%	1.93%	-65.62%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
0019	63 Neutral	HK$94.89B	83.13	0.47%	5.26%	6.44%	-95.37%
0656	42 Neutral	HK$33.89B	-7.07	-3.65%	0.44%	-8.93%	-698.78%

Fosun International Corporate Events

Fosun International Acquires Controlling Stake in Green Valley Technology

Fosun International, through its subsidiary Fosun Pharma Industrial, has entered into an agreement to acquire a controlling stake in Green Valley Technology. This acquisition involves purchasing an 8.6667% equity interest and subscribing to new capital, resulting in Fosun holding 53% of Green Valley’s enlarged equity. The transaction aims to solidify Fosun’s position in the healthcare sector, with implications for its market strategy and stakeholder interests.

The most recent analyst rating on (HK:0656) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.

Fosun Pharma Renews Strategic Supply Agreement with CQ Pharma Holdings

Fosun Pharma, a subsidiary of Fosun International, has entered into a Mutual Supply Framework Agreement with CQ Pharma Holdings, effective from January 1, 2026, to December 31, 2028. This agreement, which renews a previous arrangement, involves the supply and purchase of pharmaceutical products and related services between the two groups. The transactions are considered continuing connected transactions under Hong Kong Listing Rules but are exempt from certain requirements due to their ordinary business nature. This strategic collaboration is expected to streamline operations and strengthen Fosun Pharma’s industry positioning.

The most recent analyst rating on (HK:0656) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.

Fosun International Announces Board Composition and Roles

Fosun International Limited has announced the composition of its board of directors, including executive, non-executive, and independent non-executive directors. The announcement also details the roles and committee memberships of each board member, reflecting the company’s governance structure and leadership organization.

The most recent analyst rating on (HK:0656) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.

Fosun International Announces Director Resignation

Fosun International Limited announced the resignation of Mr. Li Shupei as a non-executive director, effective November 27, 2025, due to personal work arrangements. The company expressed gratitude for Mr. Li’s contributions and confirmed there were no disagreements or issues requiring shareholder attention, suggesting a smooth transition in the board’s composition.

The most recent analyst rating on (HK:0656) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.

Fosun Completes Major Share Disposal in HAL Privatbank

Fosun International Limited has completed the sale of its shares in Hauck Aufhäuser Lampe Privatbank AG through its subsidiary Bridge Fortune. The transaction, valued at approximately EUR 703 million, signifies a strategic move for Fosun, potentially impacting its financial positioning and focus within the financial services sector.

The most recent analyst rating on (HK:0656) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.

Fosun Pharma Initiates First Grant Under 2025 H Share RSU Scheme

Fosun Pharma has announced the first grant under its 2025 H Share RSU Scheme, reducing the number of grantees to 195 and the RSUs to 10,589,500 due to changes in eligible employees. This move is part of its strategic efforts to incentivize employees and align their interests with the company’s growth, reflecting Fosun Pharma’s ongoing commitment to enhancing shareholder value and operational efficiency.

The most recent analyst rating on (HK:0656) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.